Zacks Research lowered shares of ADMA Biologics (NASDAQ:ADMA – Free Report) from a hold rating to a strong sell rating in a report released on Tuesday,Zacks.com reports.
Several other research firms also recently commented on ADMA. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. Canaccord Genuity Group cut their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Finally, Mizuho cut their price target on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $19.00.
Get Our Latest Analysis on ADMA Biologics
ADMA Biologics Stock Down 2.8%
ADMA Biologics (NASDAQ:ADMA – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, hitting the consensus estimate of $0.19. The company had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a net margin of 32.43% and a return on equity of 39.98%. ADMA Biologics’s revenue for the quarter was down .3% on a year-over-year basis. During the same period last year, the firm earned $0.11 EPS. On average, sell-side analysts expect that ADMA Biologics will post 0.84 EPS for the current year.
Insider Buying and Selling at ADMA Biologics
In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the firm’s stock in a transaction on Monday, March 9th. The shares were sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the transaction, the chief operating officer directly owned 466,600 shares of the company’s stock, valued at $7,292,958. This trade represents a 2.12% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steve Elms purchased 7,000 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was purchased at an average cost of $15.67 per share, with a total value of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares in the company, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 3.90% of the company’s stock.
Institutional Trading of ADMA Biologics
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Western Wealth Management LLC purchased a new stake in shares of ADMA Biologics during the 1st quarter valued at $31,000. Bank of America Corp DE raised its position in shares of ADMA Biologics by 107.5% during the 1st quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock valued at $36,019,000 after buying an additional 2,071,338 shares in the last quarter. Amundi raised its position in shares of ADMA Biologics by 62.9% during the 1st quarter. Amundi now owns 51,761 shares of the biotechnology company’s stock valued at $466,000 after buying an additional 19,985 shares in the last quarter. California State Teachers Retirement System raised its position in shares of ADMA Biologics by 24.0% during the 1st quarter. California State Teachers Retirement System now owns 279,124 shares of the biotechnology company’s stock valued at $2,515,000 after buying an additional 53,988 shares in the last quarter. Finally, Royal Bank of Canada raised its position in shares of ADMA Biologics by 448.8% during the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock valued at $8,373,000 after buying an additional 759,984 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.
ADMA Biologics Company Profile
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Featured Stories
- Five stocks we like better than ADMA Biologics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
